{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:26:29Z","timestamp":1790389589578,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vancomycin, primarily excreted through the urine, is used for complicated urinary tract infections (cUTIs) caused by Gram-positive bacteria. Although serum therapeutic drug monitoring (TDM) is usually performed in vancomycin therapy, its benefits and risk factors in patients with cUTIs remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with Gram-positive bacterial cUTIs receiving serum vancomycin TDM were enrolled from three prospective, multicenter trials. Minimal inhibitory concentration (MIC) was measured by agar dilution for pathogens collected from all patients. Clinical characteristics and pharmacokinetic\/pharmacodynamic (PK\/PD) indices were analyzed between the vancomycin treatment success and failure groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 74 adult patients with cUTIs were enrolled. Median initial daily dose of vancomycin was 1.0\u00a0g (interquartile range [IQR], 1.0\u20132.0\u00a0g), given in divided doses every 12\u00a0h or as a once-daily regimen. Most concomitant antibiotics targeted Gram-negative bacteria or fungi, with very limited anti-Gram-positive co-therapy. The median serum trough concentration (C\n                      <jats:sub>min<\/jats:sub>\n                      ) of vancomycin was 9.22\u00a0mg\/L (IQR, 4.36\u201314.33\u00a0mg\/L) and 24-h area under the concentration-time curve to MIC (AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC) was 455 (IQR, 268\u2013627). Despite low attainment of the AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC 400\u2013600 target (27\/74, 36.5%), the treatment success rate was 86.5% (64\/74) and the nephrotoxicity rate was 4.1% (3\/74). Urinary pathogens isolated included\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      spp (55\/74),\n                      <jats:italic>Streptococcus<\/jats:italic>\n                      spp (10\/74), and\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (9\/74), including eight methicillin-resistant\n                      <jats:italic>S<\/jats:italic>\n                      .\n                      <jats:italic>aureus<\/jats:italic>\n                      [MRSA]). Both solid tumor and\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infection showed exploratory associations with vancomycin treatment failure. Patients with solid tumor had a lower probability of attaining the target AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC, likely due to the elevated MIC of the predominant\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      strains in this population. In contrast, patients with\n                      <jats:italic>S. aureus<\/jats:italic>\n                      -induced cUTIs achieved higher AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC levels. All isolates exhibited low MICs (\u22641\u00a0mg\/L), no heteroresistance was detected, and the predominant molecular type was clone complex 5 (CC5).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Vancomycin was effective in\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      -dominant cUTIs and had a modest response in a few MRSA cases, despite low PK\/PD target attainment. Serum C\n                      <jats:sub>min<\/jats:sub>\n                      and AUC\n                      <jats:sub>24<\/jats:sub>\n                      \/MIC showed limited association with clinical outcomes, whereas solid tumor and\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infection showed exploratory associations with treatment failure. However, TDM remains valuable for safety monitoring and individualized dosing. These findings should be validated in larger cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1772367","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:24Z","timestamp":1784175684000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Limited association between serum vancomycin pharmacokinetic\/ pharmacodynamic indices and clinical outcomes in gram-positive complicated urinary tract infections"],"prefix":"10.3389","volume":"17","author":[{"given":"Yaxin","family":"Fan","sequence":"first","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuancheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Clinical Pharmacology Research Center, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xi","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailan","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"Joint Laboratory of Hospital and Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beining","family":"Guo","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"Joint Laboratory of Hospital and Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyang","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Center, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Bian","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Clinical Pharmacology Research Center, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of People\u2019s Republic of China","place":["Shanghai, China"]},{"name":"National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/phar.2475","article-title":"Optimization of vancomycin dosing regimen in cancer patients using pharmacokinetic\/pharmacodynamic modeling","volume":"40","author":"Alqahtani","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/jac\/dkab036","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"76","author":"Brown","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/FTD.0b013e3182a458bc","article-title":"Development and validation of a new ultra-performance liquid chromatographic method for vancomycin assay in serum and its application to therapeutic drug monitoring","volume":"36","author":"Cao","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41467-025-68081-w","article-title":"Genomics reveal Staphylococcus aureus persists during long-term urinary catheterization despite antimicrobial therapy and catheter exchanges","volume":"17","author":"Duran Ramirez","year":"2026","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0134822","DOI":"10.1128\/spectrum.01348-22","article-title":"Sequence type 5 (ST5) as a possible predictor of bacterial persistence in adult patients with methicillin-resistant Staphylococcus aureus pneumonia treated with vancomycin","volume":"10","author":"Fan","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","article-title":"Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"He","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/nejmoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B10","volume-title":"M100: Performance Standards for Antimicrobial Susceptibility Testing","author":"Institute","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e01602-17","DOI":"10.1128\/AAC.01602-17","article-title":"Pharmacokinetic\/Pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia","volume":"62","author":"Jumah","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jiac.2023.07.010","article-title":"Association between ratio of area under the concentration-time curve to minimum inhibitory concentration of vancomycin and clinical outcomes in Enterococcus faecium bacteremia","volume":"29","author":"Komatsu","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European association of urology guidelines on urological infections: summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e99015","DOI":"10.7759\/cureus.99015","article-title":"Methicillin-resistant Staphylococcus aureus in urinary tract infections: a comprehensive review with insights from a north Indian cohort","volume":"17","author":"Kumar","year":"2025","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1699218","DOI":"10.3389\/fnut.2025.1699218","article-title":"Association between chronic kidney disease and sarcopenia and emerging treatment strategies","volume":"12","author":"Li","year":"2025","journal-title":"Front. Nutr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2444495","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-025-01021-0","article-title":"Prediction of area under the curve from urinary vancomycin concentrations measured using a simple method","volume":"27","author":"Oshima","year":"2025","journal-title":"AAPS J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ajic.2018.01.016","article-title":"The epidemiology of hospital-acquired urinary tract-related bloodstream infection in veterans","volume":"46","author":"Patel","year":"2018","journal-title":"Am. J. Infect. Control"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0074421","DOI":"10.1128\/AEM.00744-21","article-title":"Human urine alters methicillin-resistant Staphylococcus aureus virulence and transcriptome","volume":"87","author":"Paudel","year":"2021","journal-title":"Appl. Environ. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/17512433.2022.2121703","article-title":"A review of recent advances in the treatment of adults with complicated urinary tract infection","volume":"15","author":"Rando","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/antibiotics12111577","article-title":"Assessing clinical outcomes of vancomycin treatment in adult patients with vancomycin-susceptible Enterococcus faecium bacteremia","volume":"12","author":"Sasano","year":"2023","journal-title":"Antibiot. (Basel)"},{"key":"B26","first-page":"367","article-title":"Urine vancomycin level as a method for drug monitoring in patients with normal and decreased kidney function","volume":"11","author":"Shokouhi","year":"2017","journal-title":"Iran. J. Kidney Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ejhpharm-2022-003672","article-title":"Pharmacokinetic\/Pharmacodynamic analysis of vancomycin in patients with Enterococcus faecium bacteraemia: a retrospective cohort study","volume":"31","author":"Tochikura","year":"2024","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf460","article-title":"Clinical practice guideline by infectious diseases society of America (IDSA): 2025 guideline on management and treatment of complicated urinary tract infections: selection of antibiotic therapy for complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","article-title":"Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"Ye","year":"2016","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:21:25Z","timestamp":1784175685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1772367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":29,"alternative-id":["10.3389\/fphar.2026.1772367"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1772367","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1772367"}}